BIOS News

BioPlus Acquisition, a blank check company targeting the life sciences industry, raised $200 million by offering 20 million units at $10. The company offered 2 million more units than anticipated. It originally planned to offer 22 million units before lowering the offering in November. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. ...read more

BioPlus Acquisition, a blank check company targeting the life sciences industry, lowered the proposed deal size for its upcoming IPO on Friday. The New York, NY-based company now plans to raise $180 million by offering 18 million units at $10. The company had previously filed to offer 22 million units at the same price. Each unit now consists of one share of common stock and...read more

BioPlus Acquisition, a blank check company targeting life sciences, filed on Tuesday with the SEC to raise up to $220 million in an initial public offering. The New York, NY-based company plans to raise $220 million by offering 22 million units at $10 per unit. Each unit contains one share of common stock and one-third of a warrant, exercisable at $11.50. At the proposed deal...read more

BioMedicines, which has 5 drug candidates (3 in Phases I-III) to treat various cancers, cancelled its IPO Monday due to unfavorable market conditions. Underwriters of this deal were UBS Warburg, USB Piper Jaffray and Pacific Growth Equities. In the SEC filing, the company stated it might undertake a private offering instead....read more